We have previously reported that vitamin K 2 (VK2) has a potent apoptosis inducing activity toward various types of primary cultured leukemia cells including acute myelogenous leukemia arising from myelodysplastic syndromes (MDS). We estab- 
Introduction
Myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell disorders with dysplastic features of myeloid, erythroid and megakaryocytic lineage cells. Twenty to thirty percent of patients with MDS progress to overt myeloid leukemia (post-MDS AML) with a poor prognosis. 1, 2 The syndromes predominantly affect the elderly with a median age of 60 to 70 years. Intensive chemotherapy achieves an acceptable response rate, but the high incidence of treatment-related death and the short duration of complete remission mean that there is no survival benefit. 2, 3 High-dose chemotherapy supported by allogenic bone transplantation is the only potentially curative treatment for MDS, however, such therapy can be offered only to a few younger patients. 4, 5 Since the prog- nosis of MDS in the elderly is poor, establishment of a novel therapy for these patients is important. Vitamin K (VK) is a generic term for compounds that include phytonadione (VK1), the menaquinone series (VK2), and menadione (VK3). Physiologically, the natural K vitamins, VK1 and VK2, are known to act as cofactors for ␥-carboxylation of selected glutamates at the N-termini of prothrombin and other VK-dependent coagulation factors. The congeners of VK share a common chemical structure consisting of a naphthoquinone nucleus capable of redox cycling. VK1 has a long phytol side chain, whereas VK2 has an unsaturated side chain composed of 4-13 isoprene units (polyprenylalcohols). In contrast, VK3 is a synthetic vitamin K cogener which lacks the side chain. The structures of VK1, VK2 and VK3 are described in more detail elsewhere. 6, 7 Several lines of evidence are beginning to emerge showing that these congeners have some growth inhibitory effects on hepatoma cell lines such as Hep3B and Hep40, although the mechanisms of growth inhibition are not well understood. [8] [9] [10] [11] [12] In addition, geranylgeraniol, a polyprenylalcohol composing the side chain of VK2, was previously reported to be a potent inducer of apoptosis in tumor cell lines. 13 We have recently reported that VK2 analogs such as menaquinone (MK)-3, MK-4 and MK-5, but not VK1, induce apoptosis in primary cultured leukemia cells including post-MDS AML cells in vitro. 7 This induction of apoptosis was more potent than that caused by equivalent concentrations of polyprenylalcohols. 7 The apoptosis inducing effect of VK2 was more pronounced in leukemic blasts than in mature nonblastic cells as shown by flow cytometric analysis using the apoptosis-specific antibody APO2.7. 7, 14, 15 These results were obtained on mononuclear cells from whole bone marrow of patients with RAEB-T (refractory anemia with excess of blasts in transformation) whose bone marrow contains less than 30% blast cells. 16 Oral administration of VK2 (MK4) to a patient with MDS and myelofibrosis resulted in a reduction of the number of peripheral leukemic blast cells and hematological improvement of anemia and thrombocytopenia without any toxicity. 17 Furthermore, oral daily administration of VK2 to leukemia bearing mice demonstrated significantly prolonged survival as compared to untreated leukemic mice (Miyazawa K, personal observation). These lines of evidence suggest a positive therapeutic benefit of using non-toxic VK2 for the treatment of MDS patients.
In this report, we introduce a novel, long-term cultured MDS cell line established from a patient with MDS at a stage of RAEB-T according to FAB classification. 18 Using this cell line, we further investigated the mechanism of VK2-induced apoptosis.
Materials and methods

Profile of an MDS patient and culture conditions
A 73-year-old Japanese female with MDS, RAEB-T was referred to Kanazawa Medical University Hospital in November 1994. Chromosomal analysis of her fresh bone marrow cells showed a complex chromosomal anomaly including −4, 5q−, −7, 20q−. She soon progressed to acute myeloid leukemia, became refractory against conventional chemotherapy, and died in April 1995. Bone marrow aspiration was performed on 3 March, when 21% of her bone marrow mononuclear cells were made up of blast cells. Mononuclear cells were obtained from the heparinized bone marrow aspirate by Ficoll-Hypaque fractionation. Then, the cells were cultured with RPMI 1640 supplemented with 10% FBS.
Cytokines and reagents
Vitamin K 1 and K 2 (menaquinone (MK)-3, -4 and -5) were all supplied by Eisai Co. Ltd. (Tokyo, Japan). A specific antagonistic tetrapeptide for caspase-3 (CPP 32), Ac-Asp-Glu-Val-Asp-H, was purchased from the Peptide Institute (Osaka, Japan) and was dissolved with dimethyl sulfoxide (DMSO). Recombinant human (rh) granulocyte colony-stimulating factor (G-CSF), rh-interleukin (IL)-3, rh-stem cell factor (SCF), rhgranulocyte-macrophage colony-stimulating factor (GM-CSF), rh-thrombopoietin (TPO), and rh-erythropoietin (EPO) were kindly provided by Kirin Brewery Co. Ltd (Tokyo, Japan).
Assay of cell growth
To assess cell proliferation, WST-1 Cell Counting Kit (Dojin East, Tokyo, Japan) was used and absorption measurements were taken at 450 nm. Numbers of viable cells were determined by Trypan Blue dye exclusion test.
Immunophenotyping
Cellular antigens were analyzed by flow cytometry. Cells were washed twice with PBS containing 0.02% NaN 3 and were incubated with the following monoclonal antibodies (mAb) for 30 min at 4°C: fluorescein isothiocyanate (FITC)-conjugated mouse mAbs against human CD3 (Leu4), CD4 (Leu3a), CD8 (Leu2a) were purchased from Becton Dickinson (San Jose, CA, USA). FITC-conjugated CD11b, CD13, CD33, CD34, CD41a (glycoprotein IIb/IIIa), CD42b (glycoprotein Ib), glycophorin A were obtained from Immunotech (Marseille, France). Immunofluorescence was analyzed using an EPICS XL2 flow cytometer (Coulter Japan, Tokyo, Japan).
Chromosomal analysis
The Q-band technique was performed for chromosomal analysis as previously described. 19 
Detection of apoptosis
The extracted DNA from the treated cells was separated by 2% agarose gel electrophoresis, and the gels were stained with SYBR Green I for detecting DNA ladder formation. In addition, FITC-conjugated APO2.7 monoclonal antibody (clone 2.7), which was raised against the 38 kDa mitochondrial membrane protein (7A6 antigen) expressed by cells undergoing apoptosis, 14, 15 was purchased from Immunotech. Immunofluorescence was analyzed by flow cytometer as described above.
Assessment of caspase-3 activity
Caspase-3 activity was examined by using a substrate reagent kit which contains PhiPhiLUx-G 6 D 2 , a rhodamine-containing specific substrate (OncoImmunin, College Park, MD, USA), according to the manufacture's instruction sheet. Briefly, the cells treated with/without VK2 were incubated with the PhiPhiLUx-G 6 D 2 substrate at 37°C for 60 min and the fluorescence of the profluorescent substrate cleaved by activated caspase-3 was analyzed by flow cytometry at the FL2 channel of a BD instrument with excitation at 488 nm.
Immunoblotting
Immunoblotting was performed as previously described. 20 Briefly, cell lysates were separated by 12.5% SDS-PAGE and proteins were electrophoretically transferred on to Immobilon-P membranes (Millipore, Bedford, MA, USA). After blocking with Tris-buffered saline plus Tween-20 (50 nmol/l Tris-HCl, pH 7.4, 150 mmol/l NaCl, 0.05% Tween-20) containing 5% dry milk for 2 h, the blots were incubated with either murine anti-human BCL-2 mAb or murine anti-BAX mAb (MBL Co. Ltd, Nagoya, Japan) for 2-4 h at room temperature. Immunoreactive proteins were visualized colorimetrically.
Results
Establishment and characterization of a new MDS cell line
Separated bone marrow mononuclear cells were cultured in RPMI1640 supplemented with 10% FBS at a cell density of about 1 × 10 6 cells/ml in standing culture bottles. One third of the supernatant of cultured medium was exchanged twice a week. The cultured cells showed a stable but very slow growth rate with a doubling time of about 14 days. Therefore, the cells were split 1:2 every 2 weeks. After 12 weeks, limiting dilution was performed, and a myeloid cell line was cloned. This novel cell line, designated MDS-KZ, showed the characteristic features of blast cells with round nuclei (Figure 1a) . However, about 10% of the cells in suspension cultures consistently showed more mature myeloid characteristics with dysplasia, ie neutrophilic cells with segmented nuclei and degranulation, cells with pseudo-Pelger nuclei, and cells with hypersegmented nuclei (Figure 1b-e) . This suggests an ability of this cell line to differentiate. Cell surface antigen analysis was performed by flow cytometry and the parameters of the immunophenotype are summarized in Table 1 . Chromosomal analysis of MDS-KZ cells revealed that this cell line has a complex chromosomal abnormality including −4, 5q−, −7, 13q+, 20q−, which is consistent with the data of original bone marrow cells derived from a patient (data not shown). This cell line has now been carried for over 48 months in liquid 
Growth response to hematopoietic cytokines in MDS-KZ cells
MDS-KZ cells proliferated very slowly in RPMI1640 with 10% FBS. However, the growth rate was accelerated in the presence of various cytokines including G-CSF, IL-3, GM-CSF, SCF, and TPO (Figure 2 ). In addition to morphologic changes, cell surface antigen analysis by flow cytometry demonstrated that expression of CD13 and CD14 was enhanced after 14 day exposure to G-CSF, but not to TPO. Expression levels of CD42b and CD7 were also significantly increased in response to G-CSF, but not to TPO (Table 1) . More exhaustive characterization of this cell line according to recommendations of Drexler and Matsuo has been studied. 21 
VK2 induces apoptosis in the MDS-KZ cell line
We have previously reported that VK2 (menaquinone (MK)-3, -4 and -5) but not VK1 induces apoptosis of various types of leukemic cells in vitro. 7, 16 We also investigated the effects of VK2 on the MDS-KZ cell line. As shown in Figure 3 , a 72 h exposure to MK5 resulted in inhibition of cell growth in a dose-dependent manner (IC 50 : 5 M). After exposure to 10 M of MK5 for 48 h, MDS-KZ showed the typical features of the cells undergoing apoptosis, ie shrunken cells and fragmented nuclei (Figure 4a, right panel) . In addition, agarose gel electrophoresis of the extracted DNA from MDS-KZ cells demonstrated that ladder formation of DNA was induced in cells treated with MKs but not with VK1 and not in cells cultured in control medium (Figure 4b ). The percentage of APO2.7-positive cells was significantly increased in the presence of MK5 (Figure 4c ). These data demonstrate that VK2 induces apoptosis of MDS-KZ cells in vitro, as it does with primary leukemic cells.
Involvement of caspase-3 activation in VK2-induced apoptosis
It is well known that the ratio of anti-to pro-apoptotic molecules such as BCL-2/BAX determines the response to death signals, which cause mitochondrial dysfunction and release of cytochrome c into the cytosol, followed by activation of caspase cysteine proteases and endonuclease activation. [22] [23] [24] [25] [26] We therefore examined the potential involvement of BCL-2 and BAX proteins, which are located upstream in the apoptotic signaling pathway, and also caspase-3, a downstream effector molecule. 26 After exposure to MK3, -4 and -5, cellular proteins were lysed and immunoblotting was performed using specific antibodies against BCL-2 and BAX proteins, respectively. As shown in Figure 5 , BCL-2 protein levels were significantly reduced in response to MKs, but not to VK1 as compared with cells cultured with control medium. In contrast, BAX protein expression was up-regulated after exposure to MKs. Caspase-3 was also activated after VK2 treatment (Figure 6a ). Addition of a specific antagonistic tetrapeptide for caspase-3, Ac-DEVD-H, in MK5 containing culture medium resulted in alleviation of MK5-induced cell growth inhibition in a dose-dependent manner (Figure 6b ). In the absence of MK5, this antagonist showed no effect on MDS-KZ cell growth. In the context of apoptotic signaling, these data suggest that apoptotic signals evoked by VK2 treatment may converge caspase-3 activation through mitochondrial dysfunction by alteration of the balance between BCL-2 and BAX expression.
Discussion
We have newly established a myeloid cell line, MDS-KZ, which originated from the bone marrow of a patient with MDS in leukemic transformation. This cell line showed a complex cytogenetic anomaly including 5q−, 20q−, and −7, each of which can be frequently seen in patients with MDS, 27, 28 and has some ability to mature with dysplastic features (Figure 1 and Table 1 ). In addition, VK2 induces apoptosis in this new MDS cell line similar to its effect on cultured primary leukemia cells. 7 It is well known that VK2 as well as VK1 and VK3 are essential to blood coagulation through their action as cofactors in the carboxylation of coagulation factors by vitamin K-dependent carboxylase. All these vitamin K compounds contain a quinone group in their structure similar to some widely used antitumor agents, such as doxorubicin and daunorubicin. Each number represents the percentage of positive cells for each antigen. MDS-KZ cells were maintained with RPMI1640 supplemented with 10% FBS as a control or cultured in the presence of either rh-G-CSF (50 ng/ml) or rh-TPO (100 ng/ml) for 14 days. Cell surface antigens were analyzed by flow cytometry. Staining with isotype-matched antibodies as for negative controls revealed that the antigens showing less than 10% should be considered as 'negative'. a
The positive and the negative populations were clearly separated in flow cytogram. This is a representative result from four separate experiments.
Figure 2
Cell growth rate of MDS-KZ in the presence or absence of various cytokines. MDS-KZ cells were cultured in RPMI1640 with 10% FBS in the presence or absence of various cytokines as indicated: rh-GM-CSF 50 ng/ml, rh-IL-3 50 ng/ml, rh-G-CSF 50 ng/ml, rh-SCF 50 ng/ml, rh-TPO 25 ng/ml, rh-M-CSF 50 ng/ml, rh-EPO 6 U/ml. One third of the culture medium was exchanged every 3 days. Numbers of viable cells were determined by the Trypan Blue dye exclusion test. The experiments were done in triplicates.
Considerable evidence shows that the quinone group is involved in growth suppressive and antitumor activity through the generation of free radicals and active oxygen species. [8] [9] [10] 29 Therefore, it is not so surprising that these vitamin K compounds show some antitumor activity. However, unlike these antitumor reagents, VK2 has much less toxicity and does not induce bone marrow suppression, an important clinical bene- fit for the treatment of elderly patients with MDS. Although VK1 and VK2 share the naphthoquinone nucleus, only VK2 causes programmed cell death. The geranylgeranyl group of VK2 appears, therefore, important for the induction of apoptosis. This suggestion is supported by previous reports demonstrating polyprenylalcohols with various chain lengths expressing potent apoptosis-inducing activity toward leukemic cells. 13 However, we have shown that MK-3, -4 and -5 are more potent apoptosis inducers than polyprenylalcohols such as farnesol, geranylgeraniol and geranylfarnesol, each of which corresponds to the side chain of MK-3, -4 and -5. 7 Both a polyprenylalcohol and a naphthoquinone nucleus may thus be required for maximal apoptotic efficacy.
Recently, mitochondria have been identified as playing a central role in apoptosis. 24, 25 Apoptosis is associated with a change in the mitochondrial membrane potential, a phenomenon known as permeability transition (PT). The PT can be blocked by excess BCL-2 but not by inhibitors of caspases, indicating that PT is downstream of BCL-2 but upstream of effector caspase activation. 25, 30 BCL-2 belongs to a growing gene family with structural and functional homologies. 31 Some of these gene products, such as BCL-2, BCL-X L , MCL-1, have anti-apoptotic properties; other gene products such as BAX, BCL-X S , BAD, or BAK behave as pro-apoptotic molecules. In addition, BCL-2, BCL-XL, and BAX are capable of forming selective ion pores in membranes. 31 Thus, they may form channels on the mitochondrial membrane and a balance between pro-and anti-apoptotic gene products could regulate the PT and the release of molecules such as cytochrome c and AIF (apoptosis inducing factor). Excess pro-apoptotic mol-
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Figure 5
Expression of BCL-2 and BAX after treatment with VK1 and VK2 in MDS-KZ cells. MDS-KZ cells were treated with 10 M of VK1, MK-3, -4 and -5 for 72 h. Thereafter, the cells were lysed and the cellular proteins were separated by 12.5% SDS-PAGE, and immunoblotted with anti-BCL-2 mAb and BAX mAb, respectively. This is a representative result from three separate experiments.
Figure 6
Caspase-3 activity after treatment with MK5 in MDS-KZ cells. (a) After treatment with 10 M of MK5 for 72 h, intracellular caspase-3 activity was assessed by flow cytometry as described in Materials and methods. (b) MDS-KZ cells were treated with/without 10 M of MK5 for 72 h in the presence or absence of Ac-DEVD-H, an antagonistic tetrapeptide for caspase-3, used at concentrations of 0.1 M to 50 M. Cell growth inhibition was assessed by the WST assay as described in Materials and methods. This is a representative result from three separate experiments. ecules lead to caspase activation and apoptosis. 24, 25, 32, 33 We have shown that BCL-2 is down-regulated while BAX is upregulated after treatment of MDS-KZ cells with VK2. Concomitantly, caspase-3 is activated. Therefore, apoptotic signaling induced by VK2 treatment proceeds via mitochondrial dysfunction, which can result from various apoptotic stimuli. However, the precise mechanism, particularly the direct target molecule of VK2 in inducing apoptosis has not been determined. It is also not clear whether apoptosis by VK2 requires binding of the vitamin to the cognate nuclear receptor. This receptor has not yet been identified. Clinical case reports demonstrating the efficacy of VK2 therapy for patients with MDS are already accumulating. 17, 34 The novel cell line will be a useful tool for further studies of the molecular mechanism by which VK2 induces apoptosis. Information obtained with this novel cell line may provide important data for the clinical practice of VK2 therapy in the treatment of patients with MDS.
